BioSig Technologies, Inc. (BSGM) | Investment Case

1. Company Snapshot

1.a. Company Description

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company.The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.

The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems.BioSig Technologies, Inc.was incorporated in 2009 and is headquartered in Westport, Connecticut.

Show Full description

1.b. Last Insights on BSGM

BioSig Technologies' recent performance was driven by a Zacks Rank upgrade to #2 (Buy), indicating growing optimism about its earnings prospects. This upgrade is a positive indicator of the company's potential for future growth. Additionally, BioSig has confirmed full compliance with Nasdaq requirements, ensuring its continued listing on the Nasdaq Capital Market. This development demonstrates the company's ability to meet regulatory standards, further enhancing investor confidence.

1.c. Company Highlights

Last Price	6.1
Change Percentage	37.08%
Open	4.44
Previous Close	4.45
Market Cap ( Millions)	191
Volume	3012946
Year High	14.11
Year Low	0.23
M A 50	4.94
M A 200	3.03

FCF Yield	-26.36%
Dividend Yield	0.00%
ROE	-1474.57%
Debt / Equity	28.55%
Net Debt / EBIDTA	-3.78%
Price To Book	0.36
Price Earnings Ratio	-0.1
Price To FCF	-3.79
Price To sales	0
EV / EBITDA	-0.12

2. Streamex Corp: Tokenization Triumph Amid Losses

Streamex reported a staggering net loss of $461 million for fiscal 2025, driven largely by non‑cash accounting charges. Earnings per share slipped to –$0.04673 versus the consensus estimate of –$0.04, underscoring the company’s heavy investment phase. Revenue growth was projected at an eye‑watering 19,596 % year‑on‑year, reflecting the early traction of its GLDY product and the anticipated launch of a silver token next quarter.

Publication Date: Apr -13

                                    📋 Highlights
                                    Public Transition & GLDY Launch:
                                                Streamex transitioned to public status and launched GLDY, a tokenized gold asset with $100M+ pre-launch institutional interest.
Strong Balance Sheet:
                                                Holds $20M cash, $9.7M marketable securities, $23M assets for sale, and raised $55M in equity over 12 months with no debt.
GLDY Performance:
                                                Delivers 3.5% net lease yield; currently holds 3,000+ ounces of gold, with plans to enhance liquidity via instant minting/redemption.
Product Expansion Roadmap:
                                                Next product—tokenized silver for retail investors—targeted for Q2; explores royalties, copper, and oil/gas tokenization.
Financials & Growth Strategy:
                                                FY2025 net loss of $461M (non-cash driven), with exponential GLDY volume growth expected via liquidity and usability upgrades.

                                

Financial Snapshot

The loss margin remains high, but the company’s cash reserves of $20 million and $9.7 million in marketable securities provide a buffer for continued token issuance. With no debt and $55 million in equity raised, the P/E ratio sits at –0.11 and the P/B ratio at 0.38, indicating a valuation driven more by potential than current earnings.

GLDY Launch and Yield

GLDY, a yield‑bearing tokenized gold asset, delivers a 3.5 % net lease yield. The token is backed by 3,000 ounces of gold actively leased to industrial users, offering investors both exposure and income. The product’s early adoption has been buoyed by institutional interest exceeding $100 million in indications of interest prior to launch.

Liquidity Enhancements

Management announced an instant liquidity facility to move from a T+2 to real‑time minting and redemption. This upgrade is expected to accelerate primary market activity while a forthcoming secondary market framework will allow GLDY to trade like traditional securities, improving overall market depth and user confidence.

Marketing & Institutional Outreach

Streamex’s go‑to‑market strategy combines high‑profile conferences, a dedicated institutional sales team, and a newly built internal product sales force. Social media engagement is being amplified to broaden retail awareness, while targeted outreach aims to convert the existing pipeline into GLDY AUM.

Regulatory Landscape & CLARITY Act

GLDY is structured as a restricted Reg D security, rendering it unaffected by the CLARITY Act’s provisions on stablecoins. The act may, however, clarify secondary market operations for centralized exchanges, indirectly benefiting Streamex’s planned token ecosystems.

Balance Sheet & Capital Structure

The firm’s balance sheet is robust: $23 million in other assets held for sale, no debt, and a free cash flow yield of –24.87 %. Net debt/EBITDA stands at –0.04, reflecting a highly leveraged but debt‑free position that supports aggressive scaling initiatives.

Growth Roadmap & Future Assets

Beyond GLDY, Streamex targets a silver token launch in Q2, followed by tokenized commodities such as copper, oil, and royalties. The company’s platform, featuring seamless KYC and accreditation, is designed for scalability across assets and will integrate DeFi capabilities to enhance usability and liquidity.

3. NewsRoom

Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs

Sep -17

Source: globenewswire.com

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

Sep -10

Source: globenewswire.com

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Sep -03

Source: globenewswire.com

Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

Aug -28

Source: globenewswire.com

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Aug -15

Source: globenewswire.com

BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

Aug -14

Source: globenewswire.com

BioSig Technologies Inc. Announces Proposed Public Offering

Aug -13

Source: globenewswire.com

Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back

Jul -28

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

BioSig

Expected Growth: 14.1%

Growing demand for non-invasive cardiovascular health monitoring, increasing prevalence of cardiovascular diseases, and advancements in wearable technology drive the growth of BioSig's wearable device market.

7. Detailed Products

PURE EP

A software platform designed to improve signal fidelity and analytics for electrophysiology procedures.

PURE EP Navigator

A 3D mapping and navigation system for cardiac ablation procedures.

BioSig IDI

A novel signal processing technology for intracardiac signals.

BioSig RHYTHM

A software platform for cardiac rhythm analysis and visualization.

8. BioSig Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BioSig Technologies, Inc. operates in the medical technology industry, which has a moderate threat of substitutes. While there are alternative treatments and devices available, BioSig's proprietary technology and innovative approach to cardiac signal processing provide a competitive advantage.

Bargaining Power Of Customers

BioSig Technologies, Inc. has a diverse customer base, including hospitals, clinics, and medical research institutions. However, the company's products are highly specialized, and customers have limited bargaining power due to the unique nature of BioSig's technology.

Bargaining Power Of Suppliers

BioSig Technologies, Inc. relies on a limited number of suppliers for its components and materials. While the company has established relationships with its suppliers, it is still vulnerable to supply chain disruptions and price fluctuations.

Threat Of New Entrants

The medical technology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. BioSig Technologies, Inc. must continue to innovate and invest in research and development to stay ahead of potential competitors.

Intensity Of Rivalry

The medical technology industry is highly competitive, with numerous established players and new entrants vying for market share. BioSig Technologies, Inc. must differentiate itself through its proprietary technology and strategic partnerships to maintain its competitive edge.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	-18.37%
Debt Cost	3.95%
Equity Weight	118.37%
Equity Cost	7.44%
WACC	8.09%
Leverage	-15.52%

11. Quality Control: BioSig Technologies, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

BioSig Technologies

A-Score: 4.8/10

Value: 8.0

Growth: 6.9

Quality: 3.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

Nevro

A-Score: 4.5/10

Value: 7.4

Growth: 4.6

Quality: 3.3

Yield: 0.0

Momentum: 9.0

Volatility: 2.7

1-Year Total Return ->

NeuroOne Medical Technologies

A-Score: 4.0/10

Value: 6.8

Growth: 5.7

Quality: 4.2

Yield: 0.0

Momentum: 6.0

Volatility: 1.3

1-Year Total Return ->

Cytek Biosciences

A-Score: 3.7/10

Value: 5.7

Growth: 7.0

Quality: 4.0

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

Accelerate Diagnostics

A-Score: 3.4/10

Value: 10.0

Growth: 5.4

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Butterfly Network

A-Score: 3.2/10

Value: 6.6

Growth: 4.6

Quality: 4.1

Yield: 0.0

Momentum: 3.0

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

33.44%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.09%

BioSig Technologies, Inc. - US09073N3008

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on BSGM

1.c. Company Highlights

Weak Momentum

Medium Volatility

Fairly Valued

Earnings Beats

More Volatile

Earnings Miss

Average Quality

Stable Momentum

Strong Momentum

Cheaper

Lower Quality

Average Growth

2. Streamex Corp: Tokenization Triumph Amid Losses

Financial Snapshot

GLDY Launch and Yield

Liquidity Enhancements

Marketing & Institutional Outreach

Regulatory Landscape & CLARITY Act

Balance Sheet & Capital Structure

Growth Roadmap & Future Assets

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

BioSig

Expected Growth: 14.1%

7. Detailed Products

PURE EP

PURE EP Navigator

BioSig IDI

BioSig RHYTHM

8. BioSig Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: BioSig Technologies, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.1$

Current Price

6.1$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA